Information for Professional Attendees

September 6 - 9, 2018
Northern Kentucky Convention Center
Cincinnati Marriott at RiverCenter


UPDATE: The Cincinnati Marriot at RiverCenter and the Embassy Suites Cincinnati Rivercenter are SOLD OUT.


International Rare Lung Diseases Conference

RLDC · 2018 is an innovative conference that will bring together researchers and clinicians interested in studying rare lung diseases (RLDs) for the purpose of accelerating the advancement of RLD scientific research as well as education of clinicians caring for RLD patients. The theme for this year’s conference is “Bringing Cutting Edge Technologies to Rare Lung Disease Research”.

The objectives of this conference include:

  1. Review recent research advances for rare lung diseases.
  2. Explore cutting-edge concepts related to the diagnosis and treatment of rare lung disease patients.
  3. Provide continuing medical education (CME) credits for physicians caring for rare lung disease patients.
  4. Facilitate the translation of rare lung disease research into clinical practice ‘in real time’.
  5. Learn about emerging technologies that could potentially accelerate advancements in rare lung disease research.
  6. Incorporate the ‘patient voice’ in planning and conducting rare lung disease research.

The RLDC•2018 will offer THREE educational experiences:

International Rare Lung Diseases Conference and Technology Intensives:

Day one (Friday) will include presentations on specific rare lung diseases followed by discussion on the use of new cutting-edge technologies to accelerate the advancement of RLD research. Presentations on the impact of novel technologies on RLDs will be provided to stimulate discussion on the use of these technologies on other RLDs.

Technologies that will be explored throughout the conference will include:

  • Single Cell Analysis - AGENDA
  • Gene Editing - AGENDA
  • Personalized Medicine - AGENDA
  • Lung Imaging - AGENDA
  • Rare Lung Disease Research Coordinator Congress - AGENDA

Rare Lung Diseases Workshops

Day two (Saturday) will consist of RLD-specific workshops that will focus on how these cutting-edge technologies can be incorporated into each of the specific RLDs represented.  Workshop chairs from each group will present the most promising ideas and propose next steps during a closing plenary. Diseases that will be represented in these workshops include:

  • Lymphangioleiomyomatosis - AGENDA
  • Pulmonary Alveolar Proteinosis -  AGENDA
  • Pulmonary Langerhans Cell Histiocytosis - AGENDA
  • Sarcoidosis - AGENDA
  • Alpha-1 Antitrypsin Deficiency - AGENDA
  • Nontuberculous Mycobacteria - AGENDA
  • Pulmonary Fibrosis - AGENDA

LAMposium Patient and Family Educational Conference

Patient and family education sessions will run concurrently, with topics that cover a broad range of interests to patients and families affected by rare lung diseases. To encourage communication and collaboration between all conference attendees (researchers, clinicians and patients), all participants will dine together and are welcome to attend all sessions.

Conference Pricing - Registration Ends August 26, 2018

Professional Registration Pricing
Regular Pricing (before 8/26/2018) - $545
$50 late fee will be charged after 8/26/18

Trainees and Graduate Student Registration Pricing
Regular Pricing (before 8/26/2018) - $375
$50 late fee will be charged after 8/26/18

Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, RARE Lung Diseases Consortium and The LAM Foundation. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. 
Designation Statement: The University of Cincinnati designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
Supported by educational grant(s) from: Insmed Incorporated, Sanofi US, CSL Behring